Barriers to Implementing New CKD Treatments

Author(s):

Rajiv Agarwal, MD,Mark A. Meeker, DO, FACP, CPE

Key Takeaways

Identifying at-risk patients for CKD in Type 2 Diabetes involves assessing hypertension, family history, and blood glucose levels.
Screening tests for CKD include eGFR and UACR, essential for early detection in diabetic patients.
Early CKD detection allows timely intervention, slowing disease progression and reducing cardiovascular risks.
CKD is a significant risk factor for heart failure, highlighting the importance of early detection for cardiovascular risk management.

Panelists discuss the common barriers to implementing new chronic kidney disease (CKD) treatments and guidelines in clinical practice, as well as the role of pharmaceutical partners in overcoming these challenges to enhance CKD treatment adoption.

What are the common barriers to implementing new CKD treatments and guidelines in clinical practice?
What role do pharmaceutical partners play in overcoming challenges in CKD treatment adoption?